š ÛŒêŒŸi‰pŒêC’†š Œêj•ŽxŽ‰“’ö‚‘¬•ÀŠŽˆÀ‘S“ILesion Management‹yImaging CRO•ž–±

»åZŠé‹ÆCCROiçÎåZ•iŠJᢋƖ±ˆÏ‘õ‹@\jC‘Ž‘ŒÝŽ{çΐ¶—ü‡Žå“±“I—Տ°ŽŽé„’†Siçΐ¶Žå“±“I—Տ°ŽŽé„ÝŽ{Žx‰‡‹@\j“™“I•ïŠ‡á`‘œ•]™J“IˆÏ‘õŒ€‹†Žx‰‡•ž–±B

‹ÆÑFŠî‰—ˆÈš Û‹K’èˆ×•W€“IçΗÃá`‘œ‰ðÍ›“—pH‹ï˜a–Ô—üã‹€‹Œn“ŠŽæ“Ÿ“I‹ÆÑ
ERŠàÇåZ•šF•ïŠ‡åZÁ”»’è˜ð“IÝŒv˜a‰^s“IImaging CROˆÏ‘õ‹Æ–± 4Œ
E萉—fÐåZ Computed Tomography“Iá`Ž¿Cá`‘œ‰ðÍCŽæm 2Œ
E“§ÍåZ™ ’ʉߓÁŽê“Iá`‘œ‰ðÍ•]‘ª–@is’è—ʉðÍ 1Œ
EçΗË@Ší ’ʉ߉ðÍ“Á’èäfŠí“IŽ‰–bš€isŽ¡—ÃŒvŠcŽx‰‡ 1Œ
Eçΐ¶Žå“±“I—Տ°•]™J/Œ€‹†Žx‰‡á`‘œ‰ðÍ ‘œÉ
E‘å‹K–Í ‘å›{ŠÔ‘œÝŽ{—ü‡“Içΐ¶Žå“±—Տ°ŽŽé„ 1Œ
Eäoš —§‘Ž‡‘å›{‡ìCis —Տ°ŽŽé„ÉŸ’†Sá`‘œ—Տ°ŽŽé„›“—pCSViComputer System Validationj“I\¬‹y‘ŽŒn“\Œš 1Œ
@“™
FDA510k”F‰Â, GMP, GCP, QSR, HIPAA and Part 11 compliant (›”‰—21 CFR PART 11‰ä˜ì‰ÂˆÈˆ×ŒÚ‹qï›’ʉߓdŽqâӖŒ“IŽ¡—ÝÁ‰Ê”»’è•ñ‘j

‰ä˜ìŽx‰‡—Տ°ŽŽé„”»’èçΐ¶/ˆÏˆõ“IHì›ó‰^šz‰ÂèρC‚Á“IåZÁ”»’è˜ðI

LISIT—RçΗpá`‘œŒv—Ê‘ªŽZ›“‰Æ/›“‹Æ“I•úŽËü‰Èçΐ¶CŽg—p—Տ°ŽŽé„›“—pLesion Management—Տ°ŽŽé„ê—p“I“C’ʉßá`‘œ‰ðÍ‹Zp›”—Տ°ŽŽé„’ñ‹Ÿ‰‡•B•ÀŠŽCá`‘œ‰ðÍŠ“Ÿ“IŒ‹‰ÊŽñæisŒöŽiŠjžûCÄ—R•úŽËüfÐ›“–ålˆõisŠm”FˆÈ•Û暌‹‰Ê€Šm–³ŒëB

‹ÆŠE—BˆêF’ʉߎg—p—ÝÁ”»’蛓—p“däI“IRŠàåZ•š—Տ°ŽŽé„•ž–±
E²’E™B““I’ʉߊJ“W—Տ°ŽŽé„”»’è˜ð˜Ò”»ÐåZÁ“I•û–@CŽg—pRECIST(WHO,RECIST1.0,RECIST1.1),Immune-related Response Criteria (irRC) , Choi Criteria, Bruce D. Cheson Criteria for Lymphoma Analysis‹yPERCIST›“—p“I—Տ°ŽŽé„fÐŽx‰‡“CŽgåZÁ”»’èÁ—Š—LŽ¿—Êäo‘¬“x“I”ò–ôI
Eœn‘ª’è‰Â”\/•s”\“I•aÌC—L•W‹L«/”ñ•W‹L«•a•Ï“I‘I•ÊC“ž’ʉßBaselineAfollow-up“IDICOM“Iá`‘œŒvŽZ‘ª—ʁC“±o‘Ž‡”»’è•ñA‘S•”›‰Œ»“däIŽ©“®‰»I

—Տ°ŽŽé„•]™J›“—p““I“K—pÁ‰Ê”»’èˆêæT

’ʉߓdäI–ç‰ÂŽ©“®isåZÁ”»’èŠî€“I‰üÌiWHOšRECIST1.0->RECIST1.1šenhanced Volume RECISTj
ERECIST1.0 and RECIST1.1 (ŒÅŒ`Šà“IÁ‰Ê”»’èŠî€FTime Point‘Ž‡Á‰Ê”»’èAŽ©“®¶¬fÐ•ñ)
EWHO
EChoi Criteria (Á‰»ŠÇŠÔŽ¿ŽîᇁiGISTj“IÁ‰Ê”»’è)
EirRC (–Ɖu—Ö@Šˆ«“IÁ‰Ê”»’èŒü“±) á`‘œfÐ‹ÆŠEFLISIT¥“ú–{Žñ‰ÆÌ—p“IŒöŽi
EBruce D. Cheson 2007 (ˆ×ˆ««—Ò”bŽî‰ü’ù“IÁ‰Ê”»’è)
EPERCIST (Evolving Considerations for PET Response Criteria in Solid Tumors)
Eenhanced Volume RECIST (Ž©“®é“Ï‘ª’è/Ž©“®Žîᇍőå–ʐϐؕБI¢‹@”\FRECIST1.1j
EmRECIST HCC(ŠÌ×–EŠà“IŽ¡—ÝÁ‰Ê”»’è“Imodified RECIST)
EEASL Liver criteria
EMcDonald and RANO(ˆ×äIŽîᇓIŽ¡—ÝÁ‰Ê”»’è“ICriteriaj

Cheson2007 Œv‘ª•\ŽŠ—á

‰ä˜ìÝá`‘œfÐ—Տ°ŽŽé„ã“I—Dš
EÝ‰äŒöŽiAŽÐ’·–{lˆ×á`‘œ‰ðÍ“IçΗp/¶–œá`‘œ‰ðÍ“I›“‰ÆA•ÀŠŽ—i—L沕x“IçΗp萗ü“I—Տ°ŽŽé„‹c’菑ï›ãS鄁A“¯ŽžÝImaging CROŒöŽi—Տ°ŠJᢕ”Cš Û‡ì—Տ°ŽŽé„’†–çÏ—Ý—¹‘å—Ê“IãS鄁B‘Ž‘Œ“Iá`‘œfÐ›“‰Æ“¯Žž–琥Ý“ú–{­É“I‘S”\lË•‰Ó—Տ°ŽŽé„“Iá`‘œ™|—B
äoŸ“¯ŽžC“ú–{“Iš —§ŠàÇŒ€‹†’†S˜aúºš ŠàÇŒ€‹†’†S(DKFZ)“IÅ‘Oü“IŒ€‹†lˆõ萉—RECISTˆœŽÒ‘Ž‘Œ“ICrieteria³•sÐ’nis’ŒÚ“I’…‡ì’T“¢CŒð—¬B


LISIT“I“ÁF
EçΛ{/åZ›{/•ÛŒ’/Œ’N‰È›{/‚h‚si×Žm/”ŽŽm™Ô›{ˆÊj“I›“‰Æˆ×ŒÚ‹q›“‹Æ•ž–±B
E„œAš Û‡ì€–ځi‰p•¶•ž–±/Ž¡—χ˜‘ï›A’†•¶•ž–±/’†•¶Ž¡—χ˜‘ï›jB
E‘œÉRECIST“™“IŽ¡—ÝÁ‰Ê”»’è“I˜_•¶/‰‰uB‰äŒöŽi™¹WRECIST˜aŽ¡—ÝÁ‰Ê”»’èˆÏˆõ/ê–å“Iá`‘œfÐçΐ¶B
E—i—L‚‘¬E‘å—e—ʁE•ªŽU—Տ°ŽŽé„ÉŸ–ב¶Œn“i…Žç“ú–{Œú¶™§“®È萉—çΗÏî•ñŒn““IˆÀ‘SŠÇ—Žw•W”V4.1jB
E‚“x‰ÂMû®«F’èŠú—RçΗpá`‘œ—Տ°ŽŽé„›“–å“IŠO•”à՗§•]™J‹@\›‰Ž{ŠÄ“Cžû?B

€ŽçŠî‰—š Û/–{š ›‰K¶µãِ§“x˜aGCP“I‹³ˆçŒP—û‹K‘¥iÌ—p–Ô—üã‹³ˆçŒn“j

‰ä˜ì“IçΗÃá`‘œ‰ðÍ•ž–±Ž•ž—¹‹ÆŠE‘¶Ý“I—L萏ã–ÊŠôŒÂ€–Ú“IãžêyC—RŒP—û—L‘f“I—i—LŠe•û–Ê›“‹Æ’mŽ¯“IlËˆ×?’ñ‹Ÿ‚•iŽ¿C‚Á—Š“I•ž–±I

œnŽ–”œŽËüf—ËƖ±Cá`‘œ‰ðÍŒ€‹†’·’B15”N“I›“‰ÆCÝšŽŠi…ŽçGCPA21 CFR Part 11AFDAADICOM“™—Տ°ŽŽé„“œ–Œ‰»“Iš ÛŠî€ãAˆ×?is—L‰È›{ˆËŸ“Iš ÛÅ‚…•œ“Iá`‘œŸWC‘œ‹c’菑“Iï›B•ÀŠŽÚŽóŠeŽí‘ŠèŽæmB‰ä˜ì’ñ‹Ÿˆ×•]™JåZÁ“Ij›”‘œŽíŽŸ•a“I‰ÂMû®“Iá`‘œ‰ðÍ“B“¯ŽžC‰‡•?“I‰“’öfÐá`‘œ”zMŒn““I\ŒšI

‚Á—Šá`‘œ”»’èˆÏˆõ˜ði‰“’öà՗§—Տ°ŽŽé„”»’è˜ð‹y’†‰›”»’è˜ðj

š Û‡ì—Տ°ŽŽé„‹y˜±F‡ì—Տ°ŽŽé„ šŽŠi…zš Û‹K’è“Iá`‘œfÐŽw“±


›‰Û“IRECIST1.1’†‰›”»’è˜ð“IêŒii‰ÂˆÈis–Ô—Ýü“I”œŽËü‰Èçΐ¶is“I‰“’öˆÄ—á‰ð?j

‰ä˜ìLISIT’ʉßçΗÃá`‘œfÐ‹ZpŽxŽ‘œŽíŠàÇCŽŸ•a“Iá`‘œ”»’èI

á`‘œ”»’è˜ð“I“Á?

E Šî‰—š Û‹K’èCDICOMÉŸ“I•Û–§‰»
E šŽŠiTd“IÉŸŠÇ—˜aˆÀ‘S‰ÂèϒnÉŸ•ÛŠÇF
i”»’è˜ðŠJ?Ý“ú–{“Œ‹ž“sŒð’Ê‹É‘Ž•û•Ö“I’n•ûCˆÈ•Ö»åZŒöŽi˜a‘ŠèšdˆÊisŠÄ“j

’ʉßçΗpá`‘œ‰ðÍ“I—Տ°ŽŽé„“I’è—Êžû暁i“Á’莟Š³j

f—Éȕʏڏî
EŠ—LŽí—Þ“Iˆ««ŽîᇁiRECIST,PERCIST‘ŠèjACOPD(—Տ°ŽŽé„›‰Ž{ŒvŠcCT‘œ‹c’菑ï›FFDA”F‰ÂAá`‘œ‰ðÍ‘•’u‘I’èA‰ðÍˆÏ‘õjAŒ»‘ã•a‘Šè“Iij›”‚ŒŒšØA“œ”A•aŠ³ŽÒ“Iá`‘œ‰ðÍA铎‰–bCT‘ª’è“™jŽg—pCT,PET,SPECT,MRI“™“IŠ—L“I‰ðÍC‰ä˜ìj›”•s“¯“IŽŸŠ³A’ʉßé„æš•ªÍ•ñCˆ×?’ñ‹ŸÅ‡“K“I‹c’菑B ÝçΛ{ãCäoá`‘œ™|—Œ€‹†“IàՎ©«•s“¯C’ʉßçΗpá`‘œ‰ðÍŽè–@“I—Տ°ŽŽé„A”íŠú–]“¯Žž’ñŒðoŠî‰—“O’ê’²?˜aš Û‹K’è“I‰ÂèϓIá`‘œ‰ðÍŽè–@?–Ÿ‘˜aé„暉ߓI•ªÍ•ñB‰ä˜ì’ñ‹Ÿ?“Ÿ?Mû®“IˆÀ’è‰Âèϒná`‘œ‰ðÍ•ž–±I

—Տ°ŽŽé„‹Æ–±•ž–±?—ei‘å–ÊŒüŒ^»åZŒöŽiImaging CROŒöŽi“I•ž–±j

RECIST 1.1 and PERCISTFŠeŽí@Lesion Management Service
‰äŒöŽiA—i—Lj›”RECIST 1.1›“–å“I•ÀŠŽ—RFDAi”üš H•içÎåZ•i‹Çj”F暓IŒv—Ê‘ªŽZ“B i‰ä˜ì”Fˆ×F»åZŒöŽi•sœäŠYŽg—pŠÈšd“IŸ“—LŒvŽZ‘ª—Êé„æš“IDICOM-Viewer˜a‰“’ö?æ€á`‘œ“IŒv‘ªViewerBˆöˆ×ÝRECIST˜aPERCIST‹K’è’†A•K{•Û暌vŽZ‘ª—Ê“I€Šm«Bj •ÀŠŽC›”‰—RECISTC•K{ÝŽŸ•a•]™J—¢è‘qFDG-PETŽg”»’èX‰Á–ŸŠmC‰ÂèρB ‰ä˜ìŒöŽi“IRECIST“ˆöˆ×Œ“—e—¹‰ðÍCT˜aPET“I‹ZpCŽg“ŸŽîᇓI2DŒv‘ªC3Ž²“IŽîᇒf–Ê“IÅ’·AÅ’ZŒa“IŒv‘ªÌ“Ÿ‰Â”\B?ˆê•û–ʁCÝ‘Ž‘ŒŽxŽ”z“…“ãC‰ä˜ì–琳ÝÏ‹É‰^—p¢ŠE—̐æ“IŽxŽPERCIST“ISUV(Standard Uptake Value)˜aSUL(SUV normalized to body mass, lean body mass)“I‘œd“IROI˜aVOI“I“ŒvŒvŽZ“B(Ý“ú–{¥‘æˆêŒÂPERCIST“IŒvŽZ‹@ŽxŽH‹ïjŽg—pŠY“Œn“CŽg?•s‹Í’â—¯ÝRECIST“IŒv‘ªCšd?Žîᇕ”A”\Ž©“®“IŒvŽZo铐ψœŽÒÅ’·’ŒœlBXiˆê?“I¥C‰ä˜ì“¯Žž’ñ‹Ÿ‰ÂˆÈ‹LÚ»åZŒöŽi“I—Տ°ŽŽé„“I›‰Ž{ŒvŠc‘“Iš Û‰ÂMû®•ÀŠŽãSé„æš“I“暖Ÿ‘BiFDA”Fæšè—ü•¶Œ˜aDICOM?•i“I•iŽ¿•Û暏‘j


‰ä˜ìäo“¯‹ÆŠE“I‘Ž‘ŒŒöŽi“I•s“¯”V™|I

‰ä˜ì’ñ‹ŸFDAi”üš H•içÎåZ•iŠÇ—‹Çj”F暓I‰ÂŠm•ÛRECIST“IŒvŽZ‘ª—ÊŒ‹‰Ê³Šm“I暖Ÿ‘˜a•û•Ö”»’èçΐ¶Žg—p“IRECIST‹yPERCIST“B

Žg—pPETi—z—£Žq•úŽËÐ‘w‘œåä’uj“ICheson 2007APERCIST”»’萬ˆ×‰Â”\B

EŒvŽZ“¯Šú铎²Ð–ʁCŠ¥?Ð–ʁC–îóÐ–ÊŒã“I‹——£C”\ŽgŽîᇓI?“IÅ’·œl˜aÅ’Zœl“IŒvŽZ‘ª—ʝ̓Ÿ‰Â”\Biš€™ÒÆj

E‰ä˜ì’ñ‹Ÿ–ÊŒü»åZŒöŽiCImaging CRO萗ülˆõ“I•Û暌vŽZ‘ª—Ê?€Šm“I•¶ŒB

E”@‰Ê?Žù—v•„‡RECIST 1.1“IÝPET’†“IŒ‹‰Ê•]‘ªC‰ä˜ì—˜—pPET˜aCT“I—Z‡‹ZpCæšCT˜aPET“I‡¬ˆœŽÒ“¯ŠúŒvŽZ‘ª—ʝ̓Ÿ‰Â”\Biš€™ÒÆj

E”\?•Û‘¶RECIST“IŒv‘ªŒ‹‰Êi–Æ‹Ž?Ý—Տ°ŽŽé„”»’è˜ðŽž˜ôŒvŽZ‘ª—Ê•M‹L“I–ƒ”ρj

?•˜aŽxŽŠeŽí—Տ°ŽŽé„•¶Œ“Iï›F
?”\”»Ð”œŽËü‰Èçΐ¶C‹ZŽt”cgHelical CThác¬³Ž®—pŒê›i‘–ʐfÐ‡˜‘•ñ¥”ۍ‡“K?H
Œ»Ý‹ÆŠE—¢Cˆê•”?…•œ•s‚“Il[ËÝçΗъ萐lˆõ‘àŒÞ—¢CŠëŠQ—¹çΗpá`‘œfÐs‹Æ“IᢓWBˆ×ŸC‰ä˜ìŒöŽi—¢CŠˆ–ô˜°—Տ°Œ»ê’·’B15”N“I›“‰Æ›’‰^—pçΛ{›“‹Æ’mŽ¯˜a沕x“IãS鄁Cˆ×?ï›Š—v‹“IfÐ•ñB “¯ŽžC‰ä˜ì›’šŽŠi•ÛŽç—Տ°ŽŽé„‘Šè“I‹@–§Ž–€CÝ–¢ãS‰ß»åZŒöŽi“¯ˆÓ“Iî‹µ‰º?›”•s˜ð›’f—Ëc’菑“Iï›‘SžÜ‘õ•t‹‹—L–Œ“I‘å›{ˆœŽÒ¥Œ€‹†ŠB
ˆöˆ×C‰‰‰z¥—L–Œ“IŒ€‹†ŠC‰z—eˆÕÝ‹c’菑?™Òè¶çΐ¶ˆœŽÒ¥•úŽËü‹ZŽtŒÂl“IŽåæVˆÓŒ©B ?ŠOC›”‰—»åZŒöŽi˜Ò?C”@‰Ê–¢™Òlá`‘œfÐ›“‰Æ“I”»ÐŽ§–Ó–ÚããœnŒ€‹†ÝŽ{“IˆÓŒ©ˆœŽÒŒŽ•••s“®’nÌ—p‘Ž‹c’菑“I˜bC›’¥\•ª–`èš“II ÝLISITCž’Ê‚b‚sC‚l‚q‚hC‚o‚d‚sC•úŽËüŽ¡—Øa‚h‚‚‚‡‚‰‚Ž‚‡@‚b‚q‚n“™ì—p˜a‘€ì“I›“‰ÆC›’Ý??‘ŠèŽŸ•a“IšŽ–§“Iš Û›{p˜_•¶@ˆ×?‹KŠcÅ‡—“I•W€á`‘œ‘œ‹c’菑‹yá`‘œ‰ðÍ–@I

‰ä˜ìäo“¯‹ÆŠE“I‘Ž‘ŒŒöŽi“I•s“¯”V™|I

‰ä˜ì‰ÂˆÈˆ×?’ñ‹ŸŽg—pš Û‹K’è”F‰Â“IçΗÊíŠB“I›“–å—pŒê“I³Ž®–ŒâiŠï›“I‘œ‹c’菑C“¯Žžˆ×?’–Ÿ™Òl•¶Œo™|B

Œü—Տ°ŽŽé„‹c’菑›‰Ž{‘O“I®‡«žû?“I™ÒlF
‰ä˜ìˆ×»åZŒöŽi˜a‚h‚‚‚‡‚‰‚Ž‚‡@CRO“™—ʐg’è˜ô‘Ž›“—p“I‘œŒ`Ž®C›ó’ʉߐis›”á`‘œ‰ðÍLab“I‡—“IŽw“±CˆÈˆÛŽ‘œ‹c’菑“I‚“x®‡«B

‰ä˜ìäo“¯‹ÆŠE“I‘Ž‘ŒŒöŽi“I•s“¯”V™|I

—i—L—Տ°ãSé„15”N”V‹v“I‘œ›“‰Æ›’Ý—Տ°ŽŽé„›‰Ž{“IÝŽ{?Cˆ×?isçΗݐ‘œŒP—ûCˆÈˆÛŽ‚“x“I®‡«B

äo‘Ž‘ŒçΗÖÔ⋍‡ì“IˆÈš Û•W€Žè–@is“I?‹[“I•úŽËül铖͌^›‰é„•ž–±F
‰ä˜ìŒöŽiŽg—pŠeŽíçΗÃá`‘œfÐŠíŠBiCTCMRICPET“™j—p“I•„‡Ÿ^”ü“™š ÛŽw•W”F暓IçΗpl铖͌^iˆ×ŠÇ—á`‘œ•iŽ¿ŠŽg—p“I›‰é„ŠíÞjCÝ’ʉߒè—ʉðÍŽè–@Cé„æšžû?‘O“Iåä’u•iŽ¿“I®‡«Cˆ×?ï›çΗÊíŠB“I•Û暕ñ‘

‰ä˜ìäo“¯‹ÆŠE“I‘Ž‘ŒŒöŽi“I•s“¯”V™|I

ˆ×?’ñ‹ŸŽg—pCatPhantom“ICTåä’u“I•iŽ¿ŠÇ—CŽg—pCOPDgene Phantom“ICOPD›“—p“ICT‘•’u“I•iŽ¿ŠÇ—“™›“‹Æ“I•iŽ¿ŠÇ—B

CatPhantomˆœŽÒLung COPD Phantom“™

‰ä˜ìÏ—Ý—¹æ²•x“Il铖͌^›‰é„ãS鄁Cˆ×?’ñ‹Ÿ‚•iŽ¿“IfÐŒ‹‰Ê•ñ‘B

œäŠ³ŽÒ—v‹Cˆ×Š³ŽÒ‰îÐ??æT‘œCfÐ“I›“–å“Içΐ¶
Ÿ‹c’菑“I–Ú“ICˆ×?‰îÐÝ‘å›{•›¢çΉ@Cá`‘œ?怒†SC—Տ°ŽŽé„‹@\“™“Içΐ¶B

‰ä˜ìäo“¯‹ÆŠE“I‘Ž‘ŒŒöŽi“I•s“¯”V™|I

‰ä˜ìœn‹Zpš£‘à’†‘IUo‡“K“IlËC”hŒ­‘Œ˜ì“ž“ú–{çΛ{•úŽËü›{˜ðC“ú–{•úŽËü‹Zp›{˜ðC”üš •úŽËü›{˜ð“™‚…•œ›{˜ðCˆ×?ŸWÅV“Iî•ñB

çΗpá`‘œÉŸŸWCMaskingi“œ–Œj•ž–±F

‰ä˜ìŽg—p–k”ü•úŽËü˜ð‹cî•ñˆÏˆõ˜ð‹K’è“I”üš “IçΗpá`‘œŽ‘Œ¹’†S“I—Տ°ŽŽé„›“—p“IDICOM Maskingi“œ–Œ‰»j“Cˆ×?’ñ‹Ÿ—Տ°ŽŽé„›“—p“I—L‰È›{ˆËŸ“IÅ‡“K“IMaskingH‹ïBŠY“€ŽçDICOMš Û•W€‰»ˆÏˆõ˜ðCWorking Group18i萉——Տ°ŽŽé„“IDICOM‹@–§á`‘œ•ªÍ‹Z–@jB•ÀŠŽCŠY“Ý“ú–{‘ü—L‰ä˜ìŒöŽi”íàՉƎöžÜIÝ“ú–{C‰ä˜ì¥—Bˆêˆê‰Æ‰ÂˆÈˆ×?’ñ‹ŸÝ—Տ°ŽŽé„Žž—L˜_暎xŽ“IDICOM“œ–Œ‰»“˜aŠY““I”|ŒP•ž–±BXiˆê?“I¥C›”‰——˜—pŠY“ŠŸW“Iá`‘œŒQC‰ä˜ì’ʉߍݒ†‰›‰“’öâ‹êy“I‚“xˆÀ‘S“I‰“’öá`‘œ”zMŒn“isŠÇ—B

‰ä˜ìäo“¯‹ÆŠE“I‘Ž‘ŒŒöŽi“I•s“¯”V™|I

‰ä˜ìŒ˜Œˆ•sŽg—p•—pDICOM ViewerˆœŽÒ”ñ›“‹ÆlˆõàՎ©»ì“IDICOM Header“I“œ–Œ‰»“I

ŽæŽ§‘ã”V“I¥C‰ä˜ìŽg—p…zš Û‹K’萻ì—LžÜˆÐ«“IDICOMá`‘œ“I—Տ°›“—pMasking“B

‰ä˜ì›”»åZŒöŽi‹yis”F暓IÅI”»’è“IçÎåZ•i‹@\isšŽŠi•Û–§B“¯ŽžC‰ä˜ì‰ÂˆÈ暖ŸÝR?’†S˜a“ú–{Œú¶™§“®ÈR?‰ÈC•„‡š Û•W€“IªŸDICOM‹KŠiÝŒv“I—Տ°ŽŽé„“IŽ‘—¿C›’˜a?“IŒÂl誎„Žó“žŠmØ“I•ÛŒìB

?ŠOCŠY•„‡š Û•W€“I›“ˆ×DICOM—Տ°ŽŽé„“IMasking“Žw“±•ž–±CÝ“ú–{‘ü—LLISIT‰ÂˆÈˆ×?’ñ‹Ÿ•ž–±I”@‰Ê»åZŒöŽi•sŽ‘^Ž©ŒÈ^³Žg—p“I“¥”ې¥ˆÂÆDICOM Supplement 142“I—Տ°ŽŽé„“I‹KŠiis“œ–Œ‰»—¹CˆœŽÒis—¹œƒžé“I“œ–Œ‰»C¿—ü?‰ä˜ìCLISIT›’˜ðˆ×?’²?B

ˆ×ˆÛŽ—Տ°ŽŽé„ÉŸ“I‚•iŽ¿«“I‘Šè›”ô•ž–±F
‰ä˜ìšŽŠi€Žç•W€‹Æ–±‡˜Žw“±‘(SOP: Standard Operating Procedures)Cˆ×?isá`‘œ•]‘ªB

‰ä˜ìäo“¯‹ÆŠE“I‘Ž‘ŒŒöŽi“I•s“¯”V™|I

‰ä˜ì–çÚŽóˆÈImaging CROˆ×›“–å‹Æ–±“IŒöŽi“Iäo›“‹Æ—L萓IŽæmB

—L‰È›{ˆËŸ“Iá`‘œ‰ðÍŽè–@F
‰ä˜ìˆ×?’ñ‹Ÿ“Iá`‘œ‰ðÍŽè–@¥ãS‰ßšŽ–§“I•¶àفC›{p’²?›ó—LçΛ{ˆËŸ“I‰ÂMû®“I•û–@B“¯ŽžC‰ä˜ìˆ×?’ñ‹ŸÅ“K‡ŠY‰ðÍŽè–@“I“B‰ä˜ìˆ×?’ñ‹Ÿ“Iá`‘œ‰ðÍ‹Æ–±¥Ý‰äŒöŽi‹y˜a‰äŒöŽi—ü?‹Ù–§“ICore Lab“™’nis“IC‘ŠŽg—LÉ•SCÉç’£çΗÃá`‘œŽù—v‰ðÍC‰ä˜ì–ç”\Ý‹K’è“IŠúŒÀ?Š®¬”C–±C›óÝ®‡«‹­“I‰ðÍ‰]’[Œn“‰ºCˆ×?’ñ‹ŸÉŸ“I‰ðÍ•ñ‘B

 

‰ä˜ìäo“¯‹ÆŠE“I‘Ž‘ŒŒöŽi“I•s“¯”V™|I

‰ä˜ìäo‘å›{C‘å›{•›¢çΉ@C“ú–{š —§ŠàÇŒ€‹†Š“™›“–å‹@\—L’˜–§Ø“I‡ìCˆ×?’ñ‹ŸÅ‡“KC«™J”äÅ‚“IçΗpá`‘œ‰ðÍ•ž–±I

—Տ°ŽŽé„ŽxŽ•ž–±ˆêæT

‰ä˜ìŸcŒ}”C‰œäo‹Æ–±—L萓IŽæmI

ãS‰ßSSL‰Á–§™|—“IŽæm•Å–Ê


Email¿êy?

—Տ°ˆÄ—á“WŽŠ


‰ä˜ìŠŠJ”­“I“


IImageJ“úŒê”ŁBá`‘œ‰ðÍ“I•W€“


‹ÆŠEÅ•Ö‹X(49,800“úŒ³jŽ‰–b‰ðÍ


”xŠà«ó‰ðÍ“

—üŒn‰ä˜ì

i“üãSSSL‰Á–§@“I•Å–Ê

(Š”jLISITF§150-0044 “ú–{ “Œ‹ž“sa’J‹æ‰~ŽR’¬6”Ô7† 1F
“d˜båjáù +81 03-5428-8291

‘S‹…‡ìšì”º

760 St-Paul W, suite 101 Montreal, QC H3C 1M4

Dkfz(úºš ŠàÇŒ€‹†’†Sj˜aMINT MedicalŒöŽiŠŠJᢓIRECIST1.1›“—p“

“ú–{š “à‡ìšì”º

LISIT˜aVISUAL TechnologyŒöŽi‡ìC¬Œ÷›‰Œ»‚‘¬çΗÃá`‘œ‰ðÍI